Cost-of-illness studies: Useful for health policy?

PharmacoEconomics

Volumn 14, Issue 2, 1998, Pages 143-148

  Koopmanschap, Marc A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST OF ILLNESS; DATA ANALYSIS; FORECASTING; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; PRIORITY JOURNAL;

COST OF ILLNESS; HEALTH POLICY; HUMANS;

EID: 0031851214     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814020-00001     Document Type: Article

References (41)

1. Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision-making? Health Policy 1987; 8: 317-23
2. Hodgson TA. Cost of illness studies: no aid to decision-making? Comments on the second opinion by Shiell et al. Health Policy 1989; 11: 57-60
3. Hodgson TA. Costs of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics 1994; 6 (6): 536-52
4. van Roijen L, Rutten FFH. Cost of illness studies, policy relevance and methods [in Dutch]. T Soc Gezondheidsz 1997; 75: 184-8
5. Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. Pharmacoeconomics 1994; 6 (6): 513-22
6. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996; 9: 636-42
7. Beeck EF, Roijen Van L, Mackenbach JP. Medical costs and economic production losses due to injuries in the Netherlands. J Trauma Inj Infect Crit Care 1997; 42 (6): 1116-22
8. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155: 1595-600
9. Evers SMAA, Engel GL, Ament AJHA. Cost of stroke in the Netherlands from a societal perspective. Stroke 1997; 28: 1375-81
10. Franco K, Tamburino M, Campbell N, et al. The added costs of depression to medical care. Pharmacoeconomics 1995; 7 (4): 284-91
11. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54 (11): 405-18
12. Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 16: 665-73
13. Knapp M, Kavanagh S. Economic outcomes and costs in the treatment of schizophrenia. Clin Ther 1997; 19: 128-38
14. Krahn MD, Berka C, Langlois P, et al. Direct and indirect costs of asthma in Canada 1990. Can Med Assosc J 1996; 154 (6): 821-31
15. Lane R, McDonald G. Reducing the economic burden of depression. Int Clin Psychopharmacol 1994; 9: 229-43
16. Lissovoy de G, Lazarus SS. The economic cost of migraine. Neurology 1994; 44 Suppl. 4: s56-62
17. Magnusson S. Treatment of rheumatoid arthritis: does it affect society's cost for the disease? Br J Rheumatol 1996; 35: 791-5
18. Malone DC, Lawson KA, Smith D, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99 (1): 22-7
19. Max W. The cost of alzheimier's disease. Pharmacoeconomics 1996; 9 (1): 5-10
20. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 781-90
21. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma. Pharmacoeconomics 1993; 3 (3): 205-19
22. Midgard R, Riise T, Nyland H. Impairment, disability and handicap in multiple sclerosis. J Neurol 1996; 243: 337-44
23. Rupp A. The economic consequences of not treating depression. Br J Psychiatry 1995; 166: 29-33
24. Simell TT, Sintonen H, Hahl J, et al. Costs of insulin-dependent diabetes mellitus. Pharmacoeconomics 1996; 9 (1): 24-38
25. Stoller MK. Economic effects of insomnia. Clin Ther 1994; 16: 873-97
26. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia. Pharmacoeconomics 1995; 8 (3): 199-222
27. Weiss KB, Sullivan SD. Socio-economic burden of asthma, allergy, and other atopic illnesses. Pediatr Allergy Immunol 1994; 5 Suppl. 1: 7-12
28. Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry 1995; 40: s60-7
29. Warner DC, McCandless RR, De Nino LA, et al. Cost of diabetes in Texas, 1992. Diabetes Care 1996; 19: 1416-9
30. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995; 38: 1351-62
31. Koopmanschap MA, Rutten FFH, Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-89
32. Koopmanschap MA, Rutten FFH. Indirect costs: the consequences of production loss or increased costs of production. Med Care 1996; 34 (12): DS59-68
33. Drummond MF, O'Brien BJ, Stoddard GL, et al. Methods for economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
34. Gold M, Siegel J, Russell L, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
35. Canadian Coordinating Office of Health Technology Assessment (CCOHTA). Guidelines for economic evaluations of pharmaceuticals: Canada. Ottawa: CCOHTA. 1994
36. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analysis. Woden: Australian Department of Health, Housing and Community Services, 1990
37. Health Care Economics Consensus Group. German recommendations on health care cost analysis: Hannover Consensus, PharmacoEcon Outcomes News 1996; 56: 4-6
38. Mathers C, Penm R, Carter R, et al. Health system costs of diseases and injury in Australia 1993-94: an analysis of costs, services use and mortality for major disease and injury groups. Canberra: Australian Institute of Health and Welfare, 1998
39. Moore R, Mao Y, Zhang J, et al. Economic burden of illness in Canada, 1993. Ottawa: Ministry of Public Works and Government Services, 1997
40. National Health Service (NHS) Executive. Burdens of disease: a discussion document Wetherby: Office for National Statistics, 1996
41. Polder JJ, Meerding WJ, Koopmanschap MA, et al. Costs of diseases in the Netherlands 1994 [in Dutch]. Rotterdam: Erasmus University, 1997.